nach oben

Drugs

Erschienen in:

01.03.2021 | AdisInsight Report

Orelabrutinib: First Approval

verfasst von: Sohita Dhillon

Erschienen in: Drugs | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Dysregulation of Bruton's tyrosine kinase (BTK) signalling has been linked to various B cell malignancies and autoimmune diseases. Orelabrutinib (宜诺凯^®) is an orally administered, potent, irreversible and highly selective BTK-inhibitor being developed by InnoCare Pharma for the treatment of B cell malignancies and autoimmune diseases. In December 2020, orelabrutinib received its first approval in China for the treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), who have received at least one treatment in the past. Clinical development of orelabrutinib for various indications is underway in the USA and China. This article summarizes the milestones in the development of orelabrutinib leading to this first approval.

Vargas L, Hamasy A, Nore BF, et al. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol. 2013;78(2):130–9.CrossRef

Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton’s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE? Immunotargets Ther. 2020;9:105–10.CrossRef

Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.CrossRef

Zarrin AA, Bao K, Lupardus P, et al. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 2021;20(1):39–63.CrossRef

Shaw ML. Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects. Am J Manag Care. 2020;26(7 Spec No.):SP226–7.

NMPA China. Orelabrutinib tablets. 2021. http://app1.nmpa.gov.cn/data_nmpa/face3/dir.html. Accessed 27 Jan 2021.

InnoCare Pharma Ltd. Orelabrutinib: Chinese prescribing information. Beijing: Innocare Pharma Ltd.; 2021.

Zhang B, Zhao R, Liang R, et al. Orelabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor with superior safety profile and excellent PK/PD properties [abstract no. CT132]. In: Proceedings American Association for Cancer Research Annual Meeting. 2020.

Song Y, Liu L, Zhang M, et al. Safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study [abstract no. 755]. Blood 2019;134(Suppl. 1).

10.

Song Y, Song Y, Liu L, et al. Long-term safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study [abstract]. Blood. 2020;136(Suppl. 1):1.CrossRef

11.

Xu W, Song Y, Li Z, et al. Safety, tolerability and efficacy of orelabrutinib, once a day, to treat Chinese patients with relapsed or refractory chronic lymphocytic leukemia/small cell leukemia [abstract]. Blood. 2019;134(Suppl. 1):4319.

12.

Xu W, Song Y, Wang T, et al. Updated results from the phase II study of orelabrutinib monotherapy in Chinese patients with relapsed or refractory chronic lymphocytic leukemia/ small cell leukemia [abstract]. Blood. 2020;136(Suppl. 1):26–7.CrossRef

13.

Song Y, Xu W, Liu L, et al. Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies [abstract]. Blood. 2020;136(Suppl. 1):43.CrossRef

Titel: Orelabrutinib: First Approval
verfasst von: Sohita Dhillon
Publikationsdatum: 01.03.2021
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 4/2021
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-021-01482-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Orelabrutinib: First Approval

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis

Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records

Novel Therapy Approaches to Follicular Lymphoma

Correction to: Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records

Understanding the Chameleonic Breakthrough Cancer Pain

Tirbanibulin: First Approval